Year	Pharmacy Resident Involved?	Pharmacy Student Involved?	Citation
2026	N	N	Anokye V, Roberson A, Ware E, et al. Predictors of enrollment and cessation outcomes in a telehealth opt-out tobacco treatment program, Health Education Research, Volume 41, Issue 2, April 2026, cyag006, https://doi.org/10.1093/her/cyag006
2026	N	N	Carpenter M, Smith T, Ware E, et al. Medication Samples and Smoking Cessation Among Adults: A Randomized Clinical Trial. JAMA Netw Open. 2026;9(5):e2611418. doi:10.1001/jamanetworkopen.2026.11418
2026	Y	N	Tenn KE, Robert S, Mosley B, Rarrick C. Survey of local patterns of fentanyl exposure and harm reduction strategies in the Southeastern United States. Ment Health Clin. 2026 Jan;16(2):43-8.
2026	Y	N	Fischer D, Lutz G. D10 vs. D50 for the Treatment of Hypoglycemia in the Emergency Department. J Emerg Med. 2026 Oct:89:100-108. doi: 10.1016/j.jemermed.2026.08.009. Epub 2026 Aug 20
2026	N	N	Haley SP, Bragg S, Stem L. Resistent hypertension in adults: evaluation and treatment. Am Fam Physician. 2026 Jan;113(1):43-50.
2026	N	N	Bragg S, Haley SP, Stem L. Letter to the editor reply: resistant hypertension in adults: evaluatio and treatment. Am Fam Physician. 2026; In press.
2026	N	N	Marrison ST, Bragg SW, Tran E. Type 2 diabetes mellitus: outpatient insulin management. Am Fam Physician. 2026 Jun;113(6):542-550.
2026	N	N	Marrison ST, Bragg S, Tran E. In reply: use of automated insulin delivery systems in individuals with type 2 diabetes. Am Fam Physician. 2026; In press.
2026	N	N	Brown B, Bragg S. MBTN: fall prevention among hospitalized older adults. Am Fam Physician. In press.
2026	Y	N	Strickland KB, Neyens R, Zeigler, SM, Weeda ER, Hawn JM. A comparison of the 4Ts, HIT-Expert Probability (HEP), and Lill-Le Louët (LLL) scores in screening for heparin-induced thrombocytopenia in cardiac surgery patients. J Cardiothorac Surg. Published online September 12, 2026. doi:10.1186/s13019-026-04671-z
2026	Y	N	Dobson A, Billups K. Clinical outcomes of droperidol for agitation in trauma patients in the Emergency Department. J Trauma Nurs. 2026;33(2):109-115.
2025	Y	N	Kadi B, Condeni MS, Morrisette T, Bell C, Hamby C, Pollander A. Impact of 24-hour pharmacy call response on time to antibiotics in open fractures. Am J Health Syst Pharm. 2025 Jan: xzae398. doi: 10.1093/ajhp/zxae398.
2025	Y	N	Strickland KB, Hawn JM, Leverett S, Bell CM. A retrospective review of concurrent versus sequential administration of intrapleural tissue plasminogen activator and dornase alfa for empyemas. Pulm Pharmacol Ther. [E pub ahead of print].
2025	Y	N	Quinn M, Galascio A, Ware E, et al. Aspirin Utilization in Patients with Nonvalvular Atrial Fibrillation on Oral Anticoagulants in a Large Academic Medical Center. https://doi.org/10.1016/j.rpth.2025.102768.
2025	Y	N	Quinn M, Chapin R, Cogdill et al. Point-of-Care INR Monitoring for Patients with Antiphospholipid Syndrome. https://doi.org/10.1016/j.rpth.2025.102789.
2025	N	N	Dunn B, Foxe M, Sprott K, Hook J, Jump C. The use of octreotide in pediatric patients: Practical applications for gastrointestinal disorders and beyond: a narrative review. Nutr Clin Pract. 2025. https://aspenjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/ncp.11348
2025	N	N	Haley S, Marrison ST, Bragg S. In reply: CBT and mindfulness effective for diabetic peripheral neuropathy. Am Fam Physician. 2025 Apr;111(4):295-296.
2025	Y	Y	Muehrcke MN, Blackwelder RS, Weeda ER, Furlough LA, Shelton JE, Brace SM, Bragg SW. Evaluation of postoperative delirium in geriatric patients given acetaminophen with and without melatonin: a retrospective cohort study. Int J Psychiatry Med. 2025;60(3):254-264.
2025	Y	N	Rath A, Morrisette T, Hamby A, Burgoon R, Billups K. Cephalexin twice daily versus four times daily for the treatment of urinary tract infections diagnosed in the emergency department. Am J Emerg Med. 2025;93:80-85.
2024	N	N	Sperry JD, Loeb A, Smith MJ, Brighton TB, Ehret JA, Fermo JD, Gentili ME, Lancaster JW, Mazur JN, Spezzano K, Szwak JA. Retrospective multicenter analysis of the safety and effectivness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity. J Thromb Thrombolysis April 2024; 57: 603-612.
2024	N	N	Bell CM, Rech MA, Boateng KA, Kastotakis G, McMurray JD, Moses BA, Mueller SW, Patel GP, Roberts RJ, Sakhuja A, Setliff K, Droege CA. Ketamine in Critically Ill Adult Patients: Use, Perceptions, and Potential Barriers. Journal of Pharmacy Practice. April 2024;37(2):351-363.
2024	Y	N	Bui VT, Pfeifer C, Snelgrove DK, Neyens RR. Pain Assessment Following Opioid Administration in Aneurysmal Subarachnoid Hemorrhage Associated Headache. J Pharm Practice Apr 2024. doi 10.1177/08971900241248481. Online ahead of print. PMID 38627957
2024	N	N	Holger DJ, Althubyani A, Morrisette T, Rebold N, Tailor M. Updates in pulmonary drug-resistant tuberculosis pharmacotherapy: a focus on BPaL and BPaLM. Pharmacotherapy. 2024 Jan. doi: 10.1002/phar.2909.
2024	N	N	Condeni MS. Case Series: Perioperative management of patients in the ICU. J Am Coll Clin Pharm 2024;7:589-612.
2024	N	N	Condeni MS, Weant KA, Neyens RR, Eriksson EA, Miano TA. Safety and efficacy of fixed versus variable-dose prothrombin complex concentrate for emergent reversal of vitamin K antagonists: A systematic review and meta-analysis. Am J Emerg Med 2024;77:91-105.

Year	Pharmacy Resident Involved?	Pharmacy Student Involved?	Citation
2024	Y	N	Pizzuti M, Bailey P, Derrick C, Albrecht B, Carr AL, Covington EW, Deri CR, Green SB, Hayes J, Hobbs ALV, Mediwala Hornback K, Keil E, Lukas J, Seddon M, Taylor AD, Torrisi J, Bookstaver PB. Epidemiology and treatment of invasive Bartonella spp. infections in the United States. Infection. 2024. doi: 10.1007/s15010-024-02177-1.
2024	N	N	Davis JA, Dima D, Ahmed N, et al. Impact of frailty on outcomes after chimeric antigen receptor t cell therapy for patients with relapsed/refractory multiple myeloma. Transplantation and Cellular Therapy. 2024;30(3):298-305.
2024	N	N	Gagelmann N, Dima D, Merz M, et al. Development and validation of a prediction model of outcome after b-cell maturation antigen-directed chimeric antigen receptor t-cell therapy in relapsed/refractory multiple myeloma. JCO. 2024;42(14):1665-1675.
2024	N	N	Hashmi H, Hansen DK, Peres LC, et al. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024;109(5):1514-1524.
2024	N	N	Afrough A, Hashmi H, Hansen DK, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14(1):1-5.
2024	N	N	Zanwar S, Sidana S, Shune L, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17(1):42.
2024	N	N	Graf KC, Davis JA, Cendagorta A, et al. “fast but not so furious”?: a condensed step up dosing schedule of teclistamab for relapsed/refractory multiple myeloma. eJHaem. 2024;5(4):793-797.
2024	N	N	Davis JA, McGann M, Marini J, Hashmi H. How to manage prolonged immune effector cell-associated hematotoxicity (Icaht) related to BCMA-directed myeloma therapy. Expert Review of Anticancer Therapy. 2024;24(6):335-338.
2024	N	N	Moore DC, Granger K, Hill H, Karabinos A, Davis JA. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma. Expert Review of Hematology. 2024;17(6):197-200.
2024	N	N	Goel U, Dima D, Davis J, et al. Safety and efficacy of B cell maturation antigen directed CAR T cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis. European J of Haematology. Published online August 27, 2024:ejh.14293.
2024	N	N	Mahmoudjafari Z, Ali A, Davis J, Sandahl T, Nachar V, Mancini R. Seamless navigation of bispecific therapies: optimizing management and outpatient access with a focus on coordination. JADPRO. 2024;15(8).
2024	N	N	McGann M and Gautama B. Management of cytopenia post-chimeric antigen receptor T-cell therapy. Pharmacy Practice in Focus: Oncology. 2024 August;6(6):14-17.
2024	N	N	Wesson W, Dima D, Suleman N, Davis J, McGann M, et al. Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma. Transplantation and Cellular Therapy. 2024 June;1-9. doi: 10.1016/j.jtct.2024.06.012
2024	Y	N	Dietz L, Marini J, Hashmi H, McGann M. A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection. J Oncol Pharm Practice. 2024. doi: 10.1177/10781552241247472.
2024	Y	Y	Trac C, Zecopoulos A, Ross C, Weeda E, McGraw D. Comparison of weight-based valproic acid dosing in treatment of mental illness among obese and nonobese patients. J Clin Psychopharmacol. 2024;44:468-71.
2024	N	N	Zacholski E, MacDonald JE, Hayward S. Ocular Toxicity of Antibody-Drug Conjugates Used in Gynecologic Malignancies. Journal of Hematology Oncology Pharmacy. Accepted. In print 12/2024.
2024	Y	N	Nickelsen PM, Neyens R, Al Kasab S. Clopidogrel hyperresponsiveness and hemorrhagic complications using on-label clopidogrel dosing after pipeline embolization. J Pharm Practice 2024. Ahead of Print. doi: 10.1177/08971900241273311
2024	N	N	Amer M, Moller MH, Alshahrani M, Shehabi Y, Arabi YM, Slshamsi F, Sigurosson MI, Rehn M, Chew M, Kalliomaki M, Lewis K, Sl-Suwaidan FA, Al-Dorzi HM, Al-Fares A, Alsadoon N, Bell CM, Groth C, Park R, Mehta S, Wischmeyer P, Omeri A, Olkkola K, Alhazzani W. Ketamine Analgo-sedation for Mechanically Ventilated Critically Ill Adults: A Rapid Practice Guideline from the Saudi Critical Care Society and the Scandinavian Society of Anesthesiology and Intensive Care Medicine. Acta Anaesthesiologica Scandinavica. 2024;1–18.
2024	N	N	Amer M, Moller MH, Alshahrani M, Shehabi Y, Arabi YM, Slshamsi F, Sigurosson MI, Rehn M, Chew M, Kalliomaki M, Lewis K, Sl-Suwaidan FA, Al-Dorzi HM, Al-Fares A, Alsadoon N, Bell CM, Groth C, Park R, Mehta S, Wischmeyer P, Omeri A, Olkkola K, Alhazzani W. Ketamine Analgo-sedation for Mechanically Ventilated Critically Ill Adults: A Rapid Practice Guideline from the Saudi Critical Care Society and the Scandinavian Society of Anesthesiology and Intensive Care Medicine. Anesthesia & Analgesia ():10.1213/ANE.0000000000007173, August 29, 2024
2024	Y	N	Davis DM, Jackson K, Hoppe C. Evaluation of cost and infusion-related reactions among intravenous trastuzumab, subcutaneous trastuzumab, and trastuzumab biosimilars at an academic medical center. J Oncol Pharm Pract. 2024 Feb 12:10781552241231913. doi: 10.1177/10781552241231913. Epub ahead of print. PMID: 38347722.
2024	N	N	Cummings K, Toll B, Ware E, et al. Implementation, enrollment, and engagement in an opt-out telehealth pharmacist-assisted tobacco treatment program for patients seen in oncology outpatient clinics. Cancer. 2024; 1-11. doi:10.1002/cncr.35291
2024	N	N	Fahey MC, Carpenter MJ, Ware E, et al. Expectations and Preferences for Digital Cessation Treatment: Multimethods Study Among Older Adults Who Smoke Cigarettes. J Med Internet Res 2024;26:e52919. doi: 10.2196/52919. PMID: 39196628. PMCID: 11391153

Year	Pharmacy Resident Involved?	Pharmacy Student Involved?	Citation
2024	N	N	Nielsen EM, Ware EC, Heincelman M, Schreiner AD, Lenert LA, Toll BA. Prescription of Nicotine Replacement Therapy for Hospitalized Tobacco Users. South Med J. 2024 Aug;117(8):517-520. doi: 10.14423/SMJ.0000000000001719. PMID: 39094806.
2024	N	Y	Maldonado Yanez BV, Kerrara KE, Lueking R, Morrisette T, Brewer EE, Lewis NH, Burgoon R, Mediwala Hornback K, Hamby AC. Comparison of the impact of a system tele-antimicrobial stewardship program on the conversion of intravenous-to-oral antimicrobials in community hospitals. Antimicrob Steward Healthc Epidemiol. 2024 Oct;4(1):e159
2024	Y	N	Persha H, Thacker SA, Mediwala Hornback K, Alvira-Arill GR, Lueking R, Morrisette T. Real-world clinical characteristics and outcomes with daptomycin use in pediatric patients: a retrospective case series. Antibiotics (Basel). 2024 Sep;13(9):883.
2024	N	Y	Morrisette T, Alghamdi S, Maree MB, Dixon TC, Thacker SA. One and done? An evaluation of the clinical outcomes of single- and multi-dose dalbavancin use in the pediatric population. J Pharm Pract. 2024 Sep:8971900241285521. doi: 10.1177/08971900241285521.
2024	N	N	Hays WB, Billups K, Nicholson J, et al. 3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors. Journal of thrombosis and thrombolysis. DOI: 10.1007/s11239-03052-4.
2024	N	N	Bragg S, Brown B, DeCastro AO. Arrhythmias and sudden cardiac death. Prim Care. 2024 Mar;51(1):143-154.
2024	N	N	Bragg S, Marrison ST, Haley S. Diabetic peripheral neuropathy: prevention and treatment. Am Fam Physician. 2024;109(3):226-232.
2023	Y	N	Ngo S, Weeda E, Malloy K. Comparison of outcomes in neonates receiving cefepime or ceftazidime. J Pediatr Pharmacol Ther. 2023;28(5):439-445.
2023	Y	N	Hartley C, Morrisette T, Malloy K, Steed LL, Dixon T, Garner SS. Succesful eradication of a highly resistant Elizabethkingia anophelis species in a premature neonate with bacteremia and meningitis. Pediatr Infect Dis J. 2023 Dec;42(12):e461-e465.
2023	Y	N	Koscal LJ, Meadows H, Raux BR, Mediwala KN, Weeda E, Houston B, Jandhyala D, Hawn JM. Evaluation of the impact of nasal colonization with methicillin-resistant Staphylococcus aureus on left ventricular assist device infections. ASHE. 2022;2(1):e79
2023	N	N	Heavner MS, Cucci MD, Barlow B, Aldhaeefi M, Thompson Bastin ML, Bell CM, Eng CC, Erdman G, Hawkins WA, Li M, Rose C, Smith SE, Lankford A. Caring for two in the ICU: pharmacologic management of pregnancy-related complications. Pharmacotherapy. June 2023; 00: 1- 16.
2023	N	N	Heavner MS, Erdman G, Barlow B, Aldhaeefi M, Cucci M, Eng CC, Hawkins WA, Rose C, Smith SE, Bell CM, Lankford A, Li M, Thompson Bastin ML. Caring for two in the ICU: Pharmacotherapy in the critically ill pregnant patient. Pharmacotherapy. March 2023;43(5):403-418.
2023	N	N	Lajthia O, Almallouhi E, Ali H, Essibayi MA, Bass E, Neyens R, Anadani M, Chalhoub R, Kicielinski K, Lena J, Porto G, Sattur M, Spiotta A, Al Kasab S. Failed Mechanical Thrombectomy: prevalence, etiology, and predictors. J of Neurosurgery 2023; doi:10.3171/2022.12.JNS222152. [epub ahead of print]
2023	N	N	Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang0Birken SL, Hobbs ALV, Agree J, Perkins 3rd NB, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Scipione MR, Zhao JJ, Witucki P, Rybak MJ. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiol Spectr. 2023 Nov: e0235123.
2023	N	N	Holger DJ, El Ghali A, Bhutani N, Lev KL, Stamper K, Kebriaei R, Kunz Coyne AJ, Morrisette T, Shah R, Alexander J, Lehman SM, Rojas LJ, Marshall SH, Bonomo RA, Rybak MJ. Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models. Antimicrob Agents Chemother. 2023 Oct: e0057823.
2023	N	N	El Ghali A, Morrisette T, Alosaimy S, Lucas K, Tupayachi-Ortiz MG, Vemula R, Wadle C, Philley JV, Mejia-Chew C, Hamad Y, Steevens RW, Zeuli JD, Webb AJ, Fiske CT, Simonyan A, Cimino CL, Mammadova M, Umana VE, Hasbun R, Butt S, Molina JC, Thomas M, Kaip EA, Bouchard J, Gore TW, Howard C, Cabanilla MG, Holger DJ, Frens JJ, Barger M, Ong A, Cohen KA, Rybak MJ. Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes. Antimicrob Agents Chemother. 2023 Sep; e0082423.
2023	N	N	Morrisette T, Stamper KC, Lev KL, Kebriaei R, Holger DJ, Abdul-Mutakabbir JC, Kunz Coyne AJ, Rybak MJ. Evaluation of omadacycline alone and in combination with rifampin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacokinetic/pharmacodynamic biofilm model. Antimicrob Agents Chemother. 2023 Jun;67(6):e0131722.
2023	N	N	Tran NN, Morrisette T, Jorgensen SCJ, Orench-Benvenutti JM, Kebriaei R. Current therapies and challenges for the treatment of Staphylococcus aureus biofilm-related infections. Pharmacotherapy. 2023 May. doi: 10.1002/phar.2806.
2023	N	N	Feldman A, Sell M, et al. Safety and Immunogenicity of Live Viral Vaccines in a Mutlicenter Cohort of Pediatric Transplant Recipients. JAMA Network Open. 2023;6(10):e2337602
2023	N	N	Chudow MB, Condeni MS, Dhar S, Heavner MS, Nei AM, Bissell BD. Current Practice Review in the Management of Acute Respiratory Distress Syndrome. J Pharm Pract 2023;36(6):1454-71.
2023	N	N	Ryan KL, Jeffres M, Mediwala Hornback K, Lusardi K, Hirsch EB. Adding Antimicrobial Stewardship Pharmacists to the ID Compensation Discussion: A More Perfect Union? Clin Infect Dis. 2023:ciad722. doi: 10.1093/cid/ciad722.

Year	Pharmacy Resident Involved?	Pharmacy Student Involved?	Citation
2023	N	N	Adema J, Ahiskali A, Fida M, Mediwala Hornback K, Stevens R, Rivera C. The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis. Pathogens. 2024; 13(3): 190; https://doi.org/10.3390/pathogens13030190
2023	N	N	Lapin J, Smith R, Mediwala Hornback K, Claeys KC. Relationship between Bloodstream Infection Rapid Diagnostics and Antimicrobial Stewardship: A Narrative Review and Practical Considerations for Implementation. Pharmacotherapy. 2023 May 9. doi: 10.1002/phar.2813.
2023	N	N	Mediwala Hornback, K. 2023 ASHP Pharmacotherapy Specialty Review and Recertification Course "Infectious Diseases - Part II". BCPS Review Course Modules. American Society of Health-Systems Pharmacists. 2023.
2023	Y	N	Davis JA, Granger K, Roubal K, et al. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. Blood. 2023;141(2):200-203.
2023	N	N	Ferreri CJ, Hildebrandt MAT, Hashmi H, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13(1):1-9.
2023	N	N	Davis JA, Sborov DW, Wesson W, et al. Efficacy and safety of cd34+ stem cell boost for delayed hematopoietic recovery after bcma directed car t-cell therapy. Transplant Cell Ther. 2023;29(9):567-571.
2023	N	N	Dima D, Davis JA, Ahmed N, et al. Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience. Transplantation and Cellular Therapy. 2024;30(3):308.e1-308.e13.
2023	Y	N	Thurlapati A, Roubal K, Davis JA, et al. Stem cell mobilization for multiple myeloma patients receiving daratumumab-based induction therapy: a real- world experience. Transplantation and Cellular Therapy. 2023;29(5):340.e1-340.e4.
2023	N	N	Sidana S, Peres LC, Hashmi H, et al. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2023;109(3):777-786.
2023	Y	N	Granger K, Gaffney KJ, Davis JA. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. J Oncol Pharm Pract. 2023;29(3):722-726.
2023	N	N	Dima D, Rashid A, Davis JA, et al. Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa 1 trial eligibility criteria: A real world multicentre study. Br J Haematol. 2024;204(4):1293-1299.
2023	N	N	Wesson W, Ahmed N, Rashid A, et al. Safety and efficacy of eltrombopag in patients with post CAR T cytopenias. European J of Haematology. 2024;112(4):538-546.
2023	N	N	Peres LC, Oswald LB, Dillard CM, et al. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024;8(1):251-259.
2023	Y	N	Davis JA, Granger K, Sakowski A, et al. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma. Expert Review of Hematology. 2023;16(12):915-918.
2023	Y	N	Thurlapati A, McGann M, Davis JA, et al. Role of tixagevimab cilgavimab in preventing SARS CoV 2 in hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy recipients. Journal of Medical Virology. 2023;95(8):e29027.
2023	Y	N	McGann M, Velayati A, Roubal K, et al. Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies. Leukemia & Lymphoma. 2023;64(9):1592-1595.
2023	Y	Y	Davis JA, Thurlapati A, Weeda E, et al. Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. Ann Hematol. 2024;103(1):251-258.
2023	N	N	Davis JA, Misniakiewicz J, Hendrickson L, McGann M, Herbst A, Hess BT. Gastric adenocarcinoma following CD19-directed chimeric antigen receptor T cell therapy. Ann Hematol. 2023;102(2):461-462.
2023	N	N	Davis JA, Graham A, Hendrickson L, Hess B, Gaffney K. Incidence of Pneumocystis jirovecii pneumonia (Pjp) in patients receiving BTK inhibitors who did not receive PJP prophylaxis. Leukemia & Lymphoma. 2022;63(8):2016-2018.
2023	N	N	Khouri J, Dima D, Li H, et al. Absolute lymphocyte count and outcomes of multiple myeloma patients treated with idecabtagene vicleucel: the us myeloma immunotherapy consortium real- world experience. Transplantation and Cellular Therapy. 2024;30(8):790.e1-790.e16.
2023	N	N	Dima D, Abdallah AO, Davis JA, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor t-cell therapy. Blood Cancer J. 2024;14(1):1-9.
2023	Y	Y	Thurlapati A, Wesson W, Davis JA, et al. Impact of cytogenetic abnormalities, induction and maintenance regimens on outcomes after high-dose chemotherapy and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a decade-long real-world experience. J Hematol. 2023;12(6):243-254.
2023	Y	N	Granger K, Gaffney KJ, Smith D, et al. Real world outcomes of cpx-351 compared to traditional chemotherapy with cytarabine consolidation for treatment of secondary acute myeloid leukemia. Blood. 2023;142(Supplement 1):5922-5922.

Year	Pharmacy Resident Involved?	Pharmacy Student Involved?	Citation
2023	Y	Y	Gaffney KJ, Bakos JK, Velayati A, et al. Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. J Oncol Pharm Pract. Published online January 2, 2024:10781552231224360.
2023	N	N	McGann M, Gaffney KJ, Davis JA, Smith D, Hashmi H. Organ toxicities associated with chimeric antigen receptor T-cell therapy. Leukemia & Lymphoma. 2023;64(2):491-494.
2023	Y	N	Granger K, Roubal K, Davis JA. Novel Bispecific Antibodies for the Treatment of Multiple Myeloma and Non-Hodgkin Lymphoma. HOPA News. 2023
2023	N	N	Hall TR, MacDonald JE, Bylinowski KM, Alvarez EA, Hardesty MM, Smith JA. Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement. Gynecol Oncol. 2023 Oct;177:180-185. doi: 10.1016/j.ygyno.2023.08.017. Epub 2023 Sep 15. PMID: 37717346.
2023	N	N	Rimel BJ, Crane EK, Hou J, Nakayama J, MacDonald J, Lutz K, Makker V, O'Cearbhaill R. Tyrosine kinase inhibitor toxicities: a society of gynecologic oncology review and recommendations. Gynecol Oncol. 2023;174:148-156.
2023	Y	N	Marini J, Maldonado A, Weeda E, Hashmi H, Neppalli A, Edwards K. Efficacy, safety and cost implications of outpatient autologous hematopoietic stem cell transplant for multiple myeloma. Hematology/Oncology and Stem Cell Therapy. 2023;16(4). and Stem Cell Therapy. 2023;16(4).
2022	Y	N	Burgoon R, Hamby A, Weeda E, Raux BR, Hornback KM. Risk factors for predicting extended-spectrum ?-lactamase-producing Enterobacterales (ESBLE) infections in non-urinary isolates. Antimicrob Steward Healthc Epidemiol. 2023;3(1):e123. Published 2023 Jul 11. doi:10.1017/ash.2023.201
2022	N	N	Bixby ML, Raux BR, Bhalla A, McCoy C, Hirsch EB. Opportunities for antibiotic stewardship in emergency department of hospitalized patients with asymptomatic bactiuria: identifying risk factors for antibiotic treatment. Antimicrob Steward Healthc Epidemio. 2022 Jan;2(1):e16
2022	N	N	Vest TA, Bell CM, Adelman A, Musch KLE, Latiolais CA, Martin CY, Whalen KM. Supplying the pipeline of peer review: a call to engage new practitioners. American Journal of Health-System Pharmacy. May 2022; 79:718-20
2022	N	N	Bell CM, Vest TA, White S. Dealing with Doubt: Overcoming Imposter Syndrome in New Practitioners. American Journal of Health-System Pharmacy. March 2022; 79:421-3.
2022	N	N	Morrisette T, Alosaimy S, Lagnf AM, Frens JJ, Webb AJ, Veve MP, Stevens R, Bouchard J, Gore TW, Ansari I, Rybak MJ. Real-world, multi-center case series of patients treated with omadacycline for resistant Gram-negative pathogens. Infect Dis Ther. 2022 Aug;11(4):1715-1723.
2022	N	N	Morrisette T, Molina KC, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, Fish DN. Real-world use of tedizolid phosphate for 28 days or more: a case series describing tolerability and clinical success. Open Forum Infect Dis. 2022 May;9(6);ofac028.
2022	N	N	FahkriRavari A, Simiyu B, Morrisette T, Dayo Y, Abdul-Mutakabbir JC. Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy. Drugs Context. 2022 Jan;11:2021-8-9.
2022	N	N	Sikora AS, Ayyala D, Rech M, Blackwell SB, Campbell J, Caylor MM, Condeni MS, DePriest A, Dzierba AL, Flannery AH, Hamilton LA, Heavner MS, Horng M, Lam J, Liang E, Montero J, Murphy D, Plewa-Rusiecki AM, Sacco A, Sacha GL, Shah P, Smith MP, Smith Z, Radosevich JJ, Viella AL, The MRCICU Investigator Team. Impact of pharmacists to improve patient care in the critically ill: A large multicenter analysis using meaningful metrics. Crit Care Med 2022;50(9):1318-28.
2022	N	Y	McManus J, Ferreira J, Jones GM, Smetana K, Condeni MS, Berger K, Witenko C, Pizzi M, Erdman M. Association of DDAVP on outcomes in spontaneous acute intracerebral hemorrhage in patients on antiplatelet therapy. J Neurol Sci 2022; 434:120142.
2022	N	N	Mazur JM, Condeni MS. "Intra-abdominal Infections" in Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Lee KC, Bookstaver PB, ed. Pharmacotherapy Principles and Practice, 6th ed. New York, NY: McGraw-Hill Education 2022.
2022	N	N	Cawcutt KA, Marcelin JR, Cortes-Penfield N, Cutrell JB, Dong S, Mahoney MV, McCarty T, Mediwala Hornback K, Titanji BK, Woc-Colburn L, Schwartz IS. #SoMe the Money! Value, Strategy, & Implementation of Social Media Engagement for Infectious Diseases Trainees, Clinicians, and Divisions. Clin Infect Dis. 2022;74(Supplement_3):S229-S236. doi: 10.1093/cid/ciac063.
2022	Y	N	Beechinor RJ, Eche IM, Edmonds N…Mediwala KN, et al. Perceptions of a virtual interview process for pharmacy residents during the COVID-19 pandemic: A multisite survey of residency candidates, preceptors, and residency program directors. Am J Health-Syst Pharm. 2022;zxac130. doi: 10.1093/ajhp/zxac130.
2022	N	N	Mediwala Hornback, K. 2022 Pharmacotherapy Core Therapeutic Modules "Infectious Diseases - Part II". BCPS Review Course Modules. American Society of Health-Systems Pharmacists. 2022.
2022	Y	N	Davis J, McGann M, Shockley A, Hashmi H. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie's choice for patients with relapsed refractory multiple myeloma. Expert Review of Hematology. 2022;15(6):473-475.
2022	N	N	McGann M, Davis JA, Gaffney KJ, et al. Real-world experience and optimization of outpatient chimeric antigen receptor t cell therapy. Transplantation and Cellular Therapy. 2022;28(9):583-585.
2022	Y	N	Davis JA, Shockley A, Hashmi H. The emergence of b-cell maturation antigen (Bcma) targeting immunotherapy in multiple myeloma. J Oncol Pharm Pract. 2022;28(4):960-968.
2022	Y	N	Davis JA, Shockley A, Glode AE. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma. J Oncol Pharm Pract. 2022;28(3):686-690.

Year	Pharmacy Resident Involved?	Pharmacy Student Involved?	Citation
2022	N	N	Davis JA, Rizzieri DA, Lane AA, et al. Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (Bpdcn). Leukemia & Lymphoma. 2022;63(11):2757-2759.
2022	Y	N	Davis JA, Shockley A, Herbst A, Hendrickson L. Polatuzumab vedotin for the front-line treatment of diffuse large b-cell lymphoma: a new standard of care? J Adv Pract Oncol. 2023;14(1):67-72.
2022	Y	N	Hashmi H, Shockley A, Davis JA. 'Save the day with a Stem Cell Rescue': Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy. Bone Marrow Transplant. 2022;57(3):504-506.
2022	Y	N	Davis JA, Youngberg H, Gaffney K, Duco M, Hashmi H. 'Fast but not so Furious': Short observation time after subcutaneous Daratumumab administration is both a safe and cost-effective strategy. Clinical Lymphoma Myeloma and Leukemia. 2022;22(8):e680-e684.
2022	Y	N	Shockley A, Davis JA, Gaffney KJ, Smith D, Weeda E, Hashmi H. Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant. J Oncol Pharm Pract. 2022;28(7):1613-1616.
2022	Y	N	Shockley A, Davis JA. B-Cell Maturation Antigen Targeting CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. HOPA News. March/April, 2022
2022	N	N	Gaffney KJ, Davis JA, McGann M, et al. Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy. J Oncol Pharm Pract. 2024;30(1):151-158.
2022	N	N	Gaffney KJ, McGann M, Davis JA, Edwards KH, Hashmi H. The incidence and characteristics of VTE within 100 days of CAR T-cell therapy. Ann Hematol. 2023;102(3):683-685.
2022	N	N	Davis JA, Gaffney KJ, McGann M, et al. Fever characteristics and impact on safety and efficacy of chimeric antigen receptor t-cell therapy. Clinical Lymphoma Myeloma and Leukemia. 2023;23(1):e14-e18.
2022	N	N	Hashmi H, McGann M, Greenwell BI. Use of long-term corticosteroids in patients treated with CAR T-cell therapy. J Oncol Pharm Practice. 2022 Mar;29(2):473-476. doi: 10.1177/10781552221104816.
2022	Y	Y	Marini J, Bass B, Rennebaum J, Weeda E, Misniakiewicz J, Sion A. The Link Between Hypoalbuminemia and Oral Tyrosine Kinase Inhibitor Adverse Events in Adults with Malignant Solid tumors. J Hematol Oncol Pharm. Aug 2022;12(4):196-203.
2022	Y	N	Slane A, Robert S, Rarrick C, Weeda E. Survey of noncontrolled medication misuse patterns. Ment Health Clin 2022;12(3):199-204.
2022	n	n	Foster M, Toll B, Ware E, et al. Optimizing the Implementation of Tobacco Treatment for People with HIV: A Pilot Study. Int J Environ Res Public Health. 2022 Oct 8;19(19):12896. doi: 10.3390/ijerph191912896. PMID: 36232195; PMCID: PMC9566573.
2022	N	N	Bragg SW, Matheson E, Blackwelder R. In reply: caution before antibiotic de-escalation following negative MRSA nares testing. Am Fam Physician. 2022 Oct;106(4):362-364.
2022	N	N	Freedy JR. Serendipitous discovery: learning through the review of research. Int J Psychiatry Med. 2022 May;57(3):183-186.
2022	N	N	Christian N, Rhodes MA, Adams CS, Bragg S. Thyroid and parathyroid conditions: hypothryoidism. FP Essent. 2022 Mar;514:18-23.
2022	N	N	Rhodes MA, Adams CS, Bragg S, Christian N. Thyroid and parathyroid conditions: hyperthyroidism. FP Essent. 2022 Mar;514:11-17.
2022	N	N	Adams CS, Bragg S, Christian N, Rhodes MA. Thyroid and parathyroid conditions: thyroid nodules, cysts, and malignancies. FP Essent. 2022 Mar;514:24-29.
2022	N	N	Bragg S, Rhodes MA, Adams CS. Thyroid and parathyroid conditions: parathyroid conditions. FP Essent. 2022 Mar;514:30-38.
2021	Y	N	Burgoon R, Weeda E, Mediwala KN, Raux BR. Clinical utility of negative methicillin-resistant Staphylococcus aureus (MRSA) nasal surveillance swabs in skin and skin structure infections. Am J Infect Control. 2022;50(8):941-946. doi:10.1016/j.ajic.2021.12.005
2021	Y	N	Wiethorn EE, Harrison S, Weeda ER, Bell CM. Effectiveness and Safety of Twice- versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center. Annals of Pharmacotherapy. May 2022; 56:541-7.
2021	Y	N	Barre S, Mcelwee J, Calhoun C, Weant KA, Maldonado A, Bell CM. Review of Hematologic and Oncologic Emergencies. Advanced Emergency Nursing Journal. April-June 2022; 44:84-
2021	Y	Y	Fabick A, Hawn J, Weeda E, Goodwin AJ, Bell CM. Comparison of Extravasation Events Related to the Administration of Vasoactive Medications via a Peripheral Intravenous Line Prior to and Following Implementation of an Institutional Protocol. Journal of the American College of Clinical Pharmacy. June 2023; 6(7): 709- 717.
2021	Y	N	Morgan EP, Hawn JM, Meadows H, Houston B, Tedford RJ, Fajardo J, Perez C. Evaluation of aspirin platelet inhibition in left ventricular assist device. J Card Surg. 2021;36(12):4503-4508.
2021	N	N	Rebold et al. Early multicenter experience with imipenem-cilastatin-relebactam for Multidrug-resistance gram-negatice infections. Open Forum Infect Dis. 2021 Dec;8(12):ofab554

Year	Pharmacy Resident Involved?	Pharmacy Student Involved?	Citation
2021	N	N	Spiegel MC, Simpson A, Davis A, Philip A, Bell CM, Nadig NR, Ford DW, Goodwin AJ. Finding the Balance: A Quality Improvement Initiative to Improve Evidence-Based Isotonic Fluid Prescribing. International Journal of Medical Informatics. December 2021; 156: 104619.
2021	N	N	Ammar M, Ammar A, Condeni MS, Bell CM. Narrative Review on the Role of Vitamin C in Sepsis and Septic Shock. American Journal of Therapeutics. July 2021;28:e649-79.
2021	N	N	Bell CM, Procter L, Parli S. Asystole following concomitant intravenous administration of neostigmine and dexmedetomidine in a patient with acute colonic pseudo-obstruction. Journal of Pharmacy Practice. March 2021. doi:10.1177/08971900211001278. Online Ahead of Print.
2021	N	N	Condeni MS, Basting AT, Costello PG, DePriest A, Eriksson EA, Evans H, Hertel K, Holder AL, Kester AN, Kowalski KR, Bell CM, McLean B, Reichert M, Santibanez M, Wieruszewski PM, Newsome AS. Major publications in the critical care pharmacotherapy literature: 2019. Journal of Critical Care. April 2021. 197-205.
2021	N	N	Hecht K, Bolton S, Elavsky M, Bell CM, McElray K, Hancock B, Adams A. Navigating the Roadmap of Workplace Politics: Advice for New Practitioners. American Journal of Health-System Pharmacy. January 2021; 78:89-92.
2021	N	N	Pilch N, Sell ML, McGhee W, Venkataramanan R. Important considerations in drug therapy in pediatric transplants. Pediatric Transplantation. 2021;25:e13881
2021	N	N	Bissell B, Campbell J, Collins R, Cook C, Desai D, DeWitt J, Eche IM, Eche IJ, Elsamadisi P, Juul J, Kim SM Makowski C, Mylvaganam R, Smith A, Stancati J, Stonsifer K, Tawil J, Condeni MS. Major publications in the critical care pharmacotherapy literature: 2020. Crit Care Explor 2021; 3(12): e0590.
2021	N	N	Ammar M, Ammar A, Condeni MS, Bell CM. Vitamin C in sepsis and septic shock. Am J Ther 2021; 28(6): e649-79.
2021	N	N	Condeni MS, Basting AT, Costello PG, DePriest A, Eriksson EA, Evans H, Hertel K, Holder AL, Kester AN, Kowalski KR, Bell CM, McLean B, Reichert M, Santibanez M, Wieruszewski PM, Newsome AS. Major publications in the critical care pharmacotherapy literature: 2019, J Crit Care 2021; 62:197-205.
2021	Y	Y	Deloney L, Condeni MS, Carter C, Leon S, Privette A, Eriksson EA. Methocarbamol Reduces Opioid Use and Length of Stay in Young Adults with Traumatic Rib Fractures. Ann Pharmacother 2021;55(6):705-10.
2021	N	N	Lichvar AB, Condeni MS, Pierce DR. Preparing Pharmacy Trainees for a Future in Research and Contributing to the Medical Literature. J Am Coll Clin Pharm 2021;4(1):71-80.
2021	N	N	Green SB, Stover KR, Barber K, Bouchard JL, Brown ML, Deri CR, Francis BJ, Gauthier TP, Hayes JE, Marx AH, McGee EU, Mediwala K, Musgrove RJ, Slain D, Stramel SA, Bland CM, Bookstaver PB. A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in 2020. Open Forum Infect Dis. 2021;8(9):ofab422. doi: 10.1093/ofid/ofab422.
2021	Y	N	Takamura K, Hebbard AM, Robert S. Characterization of inpatient care for patients admitted to a psychiatric hospital with a home opioid prescription. Ment Health Clin. 2021 Mar 31;11(2):55-58. doi: 10.9740/mhc.2021.03.055. PMID: 33850683; PMCID: PMC8019545.
2021	Y	N	Mathew AM, Robert S, Ross C, Weeda E, Pruitt A. Impact of holding home stimulant(s) on agitation in a child and adolescent inpatient psychiatric population. Ment Health Clin 2021;11(2):50-54
2021	N	N	Matheson EM, Bragg SW, Blackwelder RS. Diabetes-related foot infections: diagnosis and treatment. Am Fam Physician. 2021 Oct 1;104(4):386-394.